Sivik Global Healthcare LLC Buys 4,000 Shares of Humana Inc. $HUM

Sivik Global Healthcare LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 17.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,000 shares of the insurance provider’s stock after buying an additional 4,000 shares during the quarter. Humana makes up approximately 1.8% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 15th largest position. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,601,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new position in Humana in the 1st quarter valued at approximately $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Humana by 16.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after buying an additional 158,528 shares during the last quarter. Focus Partners Wealth raised its holdings in Humana by 104.2% in the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after buying an additional 3,281 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock valued at $33,256,000 after buying an additional 2,950 shares during the last quarter. Finally, Circle Wealth Management LLC bought a new position in Humana in the 1st quarter valued at approximately $425,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $280.24 on Friday. The company has a market cap of $33.70 billion, a price-to-earnings ratio of 21.51, a price-to-earnings-growth ratio of 1.65 and a beta of 0.42. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $279.45 and a 200-day moving average of $258.13.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. Humana’s dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HUM. Barclays dropped their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a report on Friday, October 3rd. Morgan Stanley lowered their price target on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a report on Thursday, July 31st. Wells Fargo & Company raised their price target on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a report on Tuesday. Mizuho raised their price target on shares of Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Bank of America raised their price target on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $298.00.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.